Zacks Investment Research Downgrades Ziopharm Oncology Inc. (ZIOP) to Hold
Ziopharm Oncology Inc. (NASDAQ:ZIOP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
A number of other analysts also recently weighed in on the stock. Griffin Securities reissued a “buy” rating and set a $21.00 target price on shares of Ziopharm Oncology in a research report on Monday, August 15th. Wells Fargo & Co. upgraded Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. Finally, Mizuho restated a “neutral” rating and set a $5.00 price target (down from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. Ziopharm Oncology has an average rating of “Hold” and an average target price of $9.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/zacks-investment-research-downgrades-ziopharm-oncology-inc-ziop-to-hold.html
Ziopharm Oncology (NASDAQ:ZIOP) traded down 1.015% during mid-day trading on Wednesday, hitting $5.365. 475,388 shares of the stock were exchanged. The company’s market capitalization is $700.11 million. The stock has a 50 day moving average price of $5.45 and a 200 day moving average price of $6.30. Ziopharm Oncology has a 1-year low of $4.45 and a 1-year high of $14.93.
Ziopharm Oncology (NASDAQ:ZIOP) last released its earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. The firm had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.52 million. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. The business’s revenue for the quarter was up 525.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) EPS. On average, equities analysts anticipate that Ziopharm Oncology will post ($1.34) earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Royal Bank of Canada boosted its position in shares of Ziopharm Oncology by 18.8% in the second quarter. Royal Bank of Canada now owns 19,235 shares of the biotechnology company’s stock worth $105,000 after buying an additional 3,046 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Ziopharm Oncology by 2.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 468,322 shares of the biotechnology company’s stock worth $2,572,000 after buying an additional 9,672 shares in the last quarter. Stifel Financial Corp boosted its position in shares of Ziopharm Oncology by 3.1% in the second quarter. Stifel Financial Corp now owns 59,928 shares of the biotechnology company’s stock worth $329,000 after buying an additional 1,801 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its position in shares of Ziopharm Oncology by 11.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 89,527 shares of the biotechnology company’s stock worth $492,000 after buying an additional 9,003 shares in the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in shares of Ziopharm Oncology during the second quarter worth about $976,000. Institutional investors own 44.94% of the company’s stock.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.